An experienced senior executive in both private and public companies, Mr. Sperzel comes to Chembio with an outstanding record of accomplishments. His career includes over 25 years in the In Vitro Diagnostic market with extensive experience in Point of Care (POC) testing.
Most recently, Mr. Sperzel served as President and CEO of International Technidyne Corporation (ITC), a privately-held POC diagnostic company. While at ITC, he led a corporate turnaround which won the 2012 "Most Dramatic Transformation" award among Warburg Pincus-owned Healthcare companies. He also led the acquisition of Accriva Diagnostics (Accumetrics), which strengthened ITC's leadership position in POC Cardiovascular diagnostics.
Previously, Mr. Sperzel served as President at Axis-Shield where he built a successful commercial team that delivered rapid revenue growth in the United States POC market. He also held senior leadership positions at Bayer Diagnostics (Siemens Dx), Instrumentation Laboratory, and Boehringer Mannheim Diagnostics (Roche Dx). Mr. Sperzel graduated from Plymouth State College in New Hampshire, with a B.S. in Business Administration/Management. He currently serves as an advisor to the board of the Diagnostic Marketing Association.
Definitely reads that way if you look at the posts. IT has an agenda, but I can't figure it out. Either stay or go. If IT has no skin in the game, then all of his posts are sour-grapes for not understanding the diagnostics market. Some people just outstay their welcome...I wish IT luck in his market recovery.
Rick: I share your opinion. And steps are being taken today to shore up the early phase shortcomings of Chembio. (I.e. heavy reliance on Alere for sales and today's new Regulatory Hoops to jump through in the U.S.) The pieces of valuable property here are:
2) Technology that is 3rd world friendly, without need for additional equipment/readers
3) Global in market reach
This story will grow over many quarters, not just a few.
If Chembio wanted to sell, they could have, and still can...I'm sure they still have open offers from at least 2 companies that I am aware of....
Spotty response at best. Which is all on Larry. I like the guy, but everyone can tell that he is still responding as if he CLIA waiver was his only 4th Qtr goal. He needed to be able to provide lumpy 2014 guidance the best way possible and he stumbled a bit. Chembio is more than an HIV company...the investment community needs that broader vision. In my view, 2014 looks good and growing...30+ Million in revenue, Alere is a Question mark, CLIA study must be complete, some DPP test kits in women's health and other markets outside of infectious disease markets.
I agree with you...the other overhangs will not be touched until new leadership is established. Your new CEO will have a direction that maybe different than LS's. As for Q4...without the CLIA approval, steady overall yearly growth is always rather boring. Perhaps Larry should have divided the bolus of Q3 revenue into both Q3 and Q4 to make Sailing happy.
I will have to listen to the call or read the SeekingAlpha write-up to know more. I did find the 10K explanation of the CLIA hickup very interesting. No way to have foreseen the statistical error after completing a 3000 patient blinded prospective study. The test is working as manufactured....the testing populations raised an unintended question at FDA.
Their business has always been lumpy due to how purchases are made in the rest of world market, including distribution through Alere in US. One cannot make a value judgement on a lumpy business model in the timeframe of quarters.
Former Pall executive steeped in QA/QC, Marketing, Product Management, Technical Services. A good fit for today's regulated environment. Also a good fit for understanding the full deployment needs of new customers. Selling DPP requires not only a sales team, but a dedicated technical sales/support team.
Really good fit for continued growth in multiple markets.
Can we just end this particular thread? I can't even tell what you gentlemen are talking about anymore...
By the way...I am not "bashing" your idea...just providing additional "factual" information for you to make decisions. Short Term: EXAS probably goes higher for a while...then, after whatever great news they are expecting...probably the other way.
Sharon only had 630 options according to the 2013 Annual Report...so effectively, she had no ownership of shares until the transaction. As Chief Operating Officer, if the company was going to tank, I think she'd know. Strong buy...
Sentiment: Strong Buy
Toonces...i like your analysis. The best you can get out of VRML is to learn from other's experiences. There is a pattern to going "long" in micro cap stocks. If you don't learn it, you have to remain a short term or you won't survive.
Interesting basic science on MicroRNA sequences...it will be a while before therapies are created from it. Asuragen in Texas also has a diagnostic license on another micro sequence. mir-21??
If that is true, then the player is Sailing or one of the other new posters. However, based on recent climbs before earnings..the moderate rise in PPS won't be gratifying enough for them. They will need CLIA waiver to see a true hockey-stick. Mark that event as a "coming attraction."
I can't think of a single reason why anyone who is investing in a company truly watches a message board. I purchased most of my shares pre-reverse split and will hold past the purchase of Chembio, which I doubt will be happening anytime soon. With DPP's IP position and potential for continued growth...as well as the recent R&D hiring and manufacturing space addition, I believe we are in for a great ride. If recent events are the extent of the "hick-ups" as the ITs have tried to point out, then we are in much better shape than most other historical bought-out companies in the $Billion market cap category.
Hi Mo - Agreed....
My comments to location (in my mind) helps to remind me that it is the only negative I can think of....lots of forward momentum at Chembio...lots of upside ahead. For the ITs of the board, I will only change my vision when the Chembio "story" changes...which is unlikely for this strong young company with unique intellectual property.
Here is my take on negatives with Chembio:
Location.... Period. Long Island is not the hub of point of care diagnostics...
All the other negative perceptions are part of the game today. 1) FDA is always changing its opinion on what makes for a proper study/trial/conclusion...for the benefit of the US population...Chembio does it the right way, ie. do what is expected and don't fight the FDA when the rules change.
2) Alere...they are always creating new products...without Alere, Chembio would not even be a company...it would have been stalled in lawsuits from over a decade ago. Having Alere come up with a contract-breaking issue actually gives Chembio options..let's see what they decide to do.
3) CEO? There is always a need for a change of CEOs when you move from R&D to full commercialization. We are getting there...can't wait to see who they bring on board.
Wow...all these "negatives" while Chembio grows above $30MM in revenue with no debt. What's not to like?
Amazing how much space they take up on this board. I'd rather just stick to facts. So I don't need their loose opinions. If Chembio falters, I will know. Also, I can read financial statements better than all of them combined. Looking forward to another up quarter on the CC!